Stromal and tumor immune microenvironment reprogramming through multifunctional cisplatin-based liposomes boosts the efficacy of anti-PD-1 immunotherapy in pancreatic cancer

Application of ATF decorated cisplatin liposomes and anti PD-1 antibodies to mice with pancreatic cancer showed improved efficacy by enhancing drug penetration and remodeling the immunosuppressive microenvironment.